Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Price Target at $122.70

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $122.70.

Several analysts have commented on the company. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of the company. Sachetta LLC purchased a new stake in TransMedics Group in the 4th quarter worth $40,000. USA Financial Formulas bought a new position in shares of TransMedics Group in the third quarter worth about $55,000. Quarry LP grew its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI grew its position in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Price Performance

TMDX opened at $61.97 on Friday. The firm has a market cap of $2.08 billion, a PE ratio of 65.93 and a beta of 2.12. The stock has a 50-day moving average price of $70.17 and a 200-day moving average price of $116.33. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the firm posted ($0.12) earnings per share. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. Sell-side analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.